Dataset Information

Self-reported snoring is associated with chronic kidney disease in obese but not in normal-weight Chinese adults.

ABSTRACT:

Background

The relationship between sleeping disorders and chronic kidney disease (CKD) has already been reported. Snoring, a common clinical manifestation of obstructive sleep apnea-hypopnea syndrome, is of clinical value in assessing sleeping disorder severity. However, investigations of the connection between snoring and CKD are limited, especially in normal-weight populations. This study assessed the relationship between snoring frequency and CKD in obese and normal-weight people in China.

Methods

A community-based retrospective cross-sectional study of 3250 participants was performed. Study participants were divided into three groups - the regularly snoring group, occasionally snoring group, and never snoring group - based on their self-reported snoring frequency. CKD was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m². Multiple logistic regression analysis was used to explore the relevance between snoring frequency and CKD prevalence.

Results

The CKD prevalence in obese participants was higher than that in normal-weight participants. Frequent snorers had a higher prevalence of CKD than those who were not frequent snorers in the obese group. Snoring frequency was correlated with CKD prevalence in obese participants independent of age, sex, smoking and drinking status, systolic blood pressure, triglyceride level, high-density lipoprotein, and homeostasis model assessment of insulin resistance (odds ratio: 2.66; 95% CI: 1.36-5.19; p=.004), while the same relationships did not exist in normal-weight participants (odds ratio: 0.79; 95% CI: 0.32-1.98; p=.614).

Conclusions

Snoring appears to be independently associated with CKD in obese but not in normal-weight Chinese adults.

SUBMITTER: Jiang Z

PROVIDER: S-EPMC8079005 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Background: Snoring is a common condition. Previous studies have reported the relationships between snoring and metabolic syndrome (MetS) and/or its five components: hypertension, hyperglycemia, low-high density lipoprotein (low-HDL), high-triglyceride level, and abdominal obesity. However, conclusions have been inconsistent, and there has been no comprehensive summary on this. Therefore, we performed a systematic review on the relationships between snoring and MetS, including each of MetS' components. Methods: A systematic review and a meta-analysis were conducted following the Meta-analysis of Observational Studies in Epidemiology group and Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. Electronic databases including PubMed, Embase, and the Cochrane Library were searched for publications from inception to 15 July 2020. The inverse-variance weighted method was used in the meta-analysis to calculate the pooled odds ratios (ORs) and their 95% confidence intervals (CIs) to determine the association between snoring and MetS (and its components) through a fixed or random effect model. A restricted cubic spline regression model and the linear regression model were used in a two-stage dose-response meta-analysis to evaluate the non-linear and the linear trends between snoring frequency and MetS and its components. Results: A total of 40 studies with 966,652 participants were included in this study. The pooled ORs between snoring and MetS and its components, hypertension, hyperglycemia, low-HDL, high-triglyceride level, and abdominal obesity, were 1.61 (95% CI, 1.43-1.78), 1.23 (95% CI, 1.15-1.31), 1.05 (95% CI, 1.04-1.07), 1.09 (95% CI, 1.00-1.18), 1.08 (95% CI, 1.00-1.17), and 1.75 (95% CI, 1.46-2.05), respectively. Non-linear trends were detected in the five associations except for low-HDL. A linear trend was detected in the association of snoring with hypertension, hyperglycemia, low-HDL, or abdominal obesity, with ORs of 1.07 (95% CI, 1.01-1.13), 1.05 (95% CI, 1.02-1.08), 1.03 (95% CI, 1.02-1.04), and 1.17 (95% CI, 1.16-2.89), respectively. Conclusion: Snoring was a risk factor of MetS, and a dose-response relationship existed between the two. Timely intervention in identifying snorers can minimize as much as possible the risk of metabolic syndrome in those who snore.